Nature Communications (Apr 2020)
HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
- Diu T. T. Nguyen,
- Yuheng Lu,
- Karen L. Chu,
- Xuejing Yang,
- Sun-Mi Park,
- Zi-Ning Choo,
- Christopher R. Chin,
- Camila Prieto,
- Alexandra Schurer,
- Ersilia Barin,
- Angela M. Savino,
- Saroj Gourkanti,
- Payal Patel,
- Ly P. Vu,
- Christina S. Leslie,
- Michael G. Kharas
Affiliations
- Diu T. T. Nguyen
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Yuheng Lu
- Computational Biology Program, Memorial Sloan Kettering Cancer Center
- Karen L. Chu
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Xuejing Yang
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Sun-Mi Park
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Zi-Ning Choo
- Weill Cornell School of Medical Sciences
- Christopher R. Chin
- Weill Cornell School of Medical Sciences
- Camila Prieto
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Alexandra Schurer
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Ersilia Barin
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Angela M. Savino
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Saroj Gourkanti
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Payal Patel
- Weill Cornell School of Medical Sciences
- Ly P. Vu
- Terry Fox Laboratory, British Columbia Cancer Research Centre
- Christina S. Leslie
- Computational Biology Program, Memorial Sloan Kettering Cancer Center
- Michael G. Kharas
- Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-15814-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
The identification of mRNA targets for RNA binding proteins (RBP) in stem cells is difficult due to the limited number of available cells. Here, as a proof-of-principle, the authors adapt the HyperTRIBE method to find that an RBP, MSI2, has increased RNA binding in leukemic compared with normal stem cells for selective regulation of oncogenic genes.
